The global radioligand therapies market size 2026 is on a steep growth trajectory. Valued at USD 3.17 billion in 2025, it is projected to climb from USD 4.23 billion in 2026 to USD 29.54 billion by 2034, representing a compound annual growth rate (CAGR) of 27.51% over the forecast period.
Radioligand therapies sit at the intersection of radiation oncology and precision oncology. They work by chemically linking a targeting molecule (ligand) to a therapeutic radioisotope — most commonly Lutetium-177 (Lu-177) — to deliver targeted, systemic radiation to cancer cells while minimizing damage to healthy tissue.
Key Market Drivers
Regulatory Approvals Expanding the Patient Base are the foremost growth catalyst. In March 2025, the U.S. FDA approved Novartis AG's PLUVICTO for use earlier in the prostate cancer treatment pathway — specifically after one Androgen Receptor Pathway Inhibitor (ARPI) therapy and before chemotherapy. This single approval approximately tripled the eligible patient population for the therapy, significantly amplifying market value potential.
Rising incidences of advanced prostate cancer and the long survivorship associated with Neuroendocrine Tumors (NETs) further sustain demand for these therapies on a consistent basis.
Premium Pricing and Pipeline Momentum also fuel growth. A growing number of emerging companies hold pipeline candidates in late-stage trials, and upcoming regulatory decisions — such as the FDA's PDUFA date of August 28, 2026, for ITM-11 (n.c.a. 177Lu-edotreotide) in gastroenteropancreatic NETs — point to continued market expansion.
Get a Free Sample PDF - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/radioligand-therapies-market-115467
Market Restraints and Challenges
Despite strong momentum, the market faces significant operational hurdles. Short-lived radioisotopes create complex, time-sensitive supply chains prone to bottlenecks. Limited manufacturing capacity, a shortage of qualified nuclear medicine sites, and insufficient trained staff are barriers that prevent demand from fully translating into treated patient volumes.
A real-world example emerged in June 2025 when Telix Pharmaceuticals reported a shortage of gallium-68 tracers in Portugal, resulting in a national waiting list of up to six months for prostate cancer diagnostics. Additionally, companion imaging requirements — such as PSMA PET scans — add a layer of dependency that can slow therapy access in under-resourced regions.
Segmentation Highlights
By Product: Lutetium Lu 177 Vipivotide Tetraxetan (PLUVICTO) holds the dominant product share, driven by strong sales and its expanded early-stage indication. Lutetium Lu 177 Dotatate (LUTATHERA) is projected to grow at a CAGR of 19.35%.
By Indication: Prostate cancer commands the largest indication share, supported by a wide patient population and the well-validated PSMA diagnostic-to-therapy workflow. Neuroendocrine tumors are forecast to grow at 18.15% CAGR.
By Target: The PSMA segment leads, owing to high diagnostic contrast and clear patient selection criteria that support favorable payer decisions. The "Others" target segment — representing novel targets — is projected to grow at a remarkable 45.12% CAGR, signaling a broadening therapeutic frontier.
By End User: Tertiary care academic and comprehensive cancer centers hold the largest share, as they possess the specialized nuclear medicine infrastructure and radiation safety protocols required for RLT administration. Specialized nuclear medicine centers are anticipated to grow at 22.41% CAGR.
Regional Outlook
North America dominates globally, holding 81.07% of the market in 2025 at USD 2.57 billion. The U.S. alone is estimated at approximately USD 3.20 billion in 2026, underpinned by reimbursement maturity, high PET diagnostic penetration, and concentrated theranostics centers.
Europe is the fastest-growing region, expected to record the highest CAGR of 38.87% and reach USD 0.56 billion in 2026. Academic leadership in nuclear medicine and strong NETs therapy adoption drive this growth. Germany and the U.K. are the leading country markets within the region.
Asia Pacific reached USD 0.15 billion in 2025, ranking third globally. China (USD 0.05 billion) and Japan (USD 0.04 billion) lead the region, though infrastructure gaps remain a barrier to faster adoption.
Competitive Landscape
Novartis AG dominates the market, holding the two cornerstone approved products — PLUVICTO and LUTATHERA — and continues to invest in manufacturing readiness. In November 2025, the company opened a new 100,000-square-foot RLT manufacturing facility in Carlsbad, California.
Other major players include Bristol-Myers Squibb, AstraZeneca, and Eli Lilly and Company, each building out their RLT pipelines. In July 2025, Bristol Myers Squibb opened a 77,000-square-foot radiopharmaceutical facility in Indianapolis for next-generation alpha-emitting therapies using actinium-225.
A critical emerging trend is the industrialization of RLT supply chains, with companies investing in multi-site manufacturing networks, in-house isotope supply, and long-term contracts to ensure repeatable end-to-end delivery from discovery through distribution.
Outlook
The radioligand therapies market represents one of the most dynamic growth opportunities in oncology. With regulatory tailwinds, an expanding patient base, increasing manufacturing scale, and a broadening target landscape beyond PSMA and somatostatin receptors, the market is poised to nearly sevenfold in value by 2034. The primary challenge — and opportunity — lies in solving infrastructure and isotope supply constraints to convert clinical demand into widespread, equitable patient access globally.